| MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants V Summa, SW Ludmerer, JA McCauley, C Fandozzi, C Burlein, G Claudio, ... Antimicrobial agents and chemotherapy 56 (8), 4161-4167, 2012 | 302 | 2012 |
| Discovery of MK‐8742: an HCV NS5A inhibitor with broad genotype activity CA Coburn, PT Meinke, W Chang, CM Fandozzi, DJ Graham, B Hu, ... ChemMedChem 8 (12), 1930-1940, 2013 | 244 | 2013 |
| Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor JA McCauley, CJ McIntyre, MT Rudd, KT Nguyen, JJ Romano, ... Journal of medicinal chemistry 53 (6), 2443-2463, 2010 | 201 | 2010 |
| Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor S Harper, JA McCauley, MT Rudd, M Ferrara, M DiFilippo, B Crescenzi, ... ACS medicinal chemistry letters 3 (4), 332-336, 2012 | 200 | 2012 |
| Molecular modeling based approach to potent P2− P4 macrocyclic inhibitors of hepatitis C NS3/4a protease NJ Liverton, MK Holloway, JA McCauley, MT Rudd, JW Butcher, ... Journal of the American Chemical Society 130 (14), 4607-4609, 2008 | 167 | 2008 |
| MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease NJ Liverton, SS Carroll, J DiMuzio, C Fandozzi, DJ Graham, D Hazuda, ... Antimicrobial agents and chemotherapy 54 (1), 305-311, 2010 | 152 | 2010 |
| Discovery of a 3-(4-pyrimidinyl) indazole (MLi-2), an orally available and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor that reduces brain kinase activity JD Scott, DE DeMong, TJ Greshock, K Basu, X Dai, J Harris, A Hruza, ... Journal of medicinal chemistry 60 (7), 2983-2992, 2017 | 128 | 2017 |
| Hepatitis C virus NS3/4a protease inhibitors JA McCauley, MT Rudd Current opinion in pharmacology 30, 84-92, 2016 | 122 | 2016 |
| Dual plasmepsin-targeting antimalarial agents disrupt multiple stages of the malaria parasite life cycle P Favuzza, M de Lera Ruiz, JK Thompson, T Triglia, A Ngo, RWJ Steel, ... Cell host & microbe 27 (4), 642-658. e12, 2020 | 111 | 2020 |
| HCV NS3 protease inhibitors MK Holloway, NJ Liverton, SW Ludmerer, JA McCauley, DB Olsen, ... US Patent 7,470,664, 2008 | 81 | 2008 |
| NR2B-Selective N-Methyl-d-aspartate Antagonists: Synthesis and Evaluation of 5-Substituted Benzimidazoles JA McCauley, CR Theberge, JJ Romano, SB Billings, KD Anderson, ... Journal of medicinal chemistry 47 (8), 2089-2096, 2004 | 77 | 2004 |
| Orally efficacious NR2B-selective NMDA receptor antagonists CF Claiborne, JA McCauley, BE Libby, NR Curtis, HJ Diggle, ... Bioorganic & Medicinal Chemistry Letters 13 (4), 697-700, 2003 | 74 | 2003 |
| Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino) methyl] piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl … NJ Liverton, RA Bednar, B Bednar, JW Butcher, CF Claiborne, ... Journal of medicinal chemistry 50 (4), 807-819, 2007 | 64 | 2007 |
| Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors S Harper, V Summa, NJ Liverton, JA McCauley US Patent 7,973,040, 2011 | 59 | 2011 |
| Bismacrocyclic inhibitors of hepatitis C NS3/4a protease JA McCauley, MT Rudd, KT Nguyen, CJ McIntyre, JJ Romano, KJ Bush, ... Angewandte Chemie 120 (47), 9244-9247, 2008 | 53 | 2008 |
| Design and synthesis of piperazine sulfonamide cores leading to highly potent HIV-1 protease inhibitors CJ Bungard, PD Williams, J Schulz, CM Wiscount, MK Holloway, ... ACS medicinal chemistry letters 8 (12), 1292-1297, 2017 | 43 | 2017 |
| HCV NS3 protease inhibitors MK Holloway, NJ Liverton, SW Ludmerer, JA McCauley, D Olsen, ... US Patent 7,879,797, 2011 | 41 | 2011 |
| Preclinical pharmacology and pharmacokinetics of CERC‐301, a GluN2B‐selective N‐methyl‐D‐aspartate receptor antagonist R Garner, S Gopalakrishnan, JA McCauley, RA Bednar, SL Gaul, ... Pharmacology research & perspectives 3 (6), e00198, 2015 | 39 | 2015 |
| Discovery of MK-1220: A macrocyclic inhibitor of hepatitis C virus NS3/4A protease with improved preclinical plasma exposure MT Rudd, JA McCauley, JW Butcher, JJ Romano, CJ McIntyre, ... ACS Medicinal Chemistry Letters 2 (3), 207-212, 2011 | 39 | 2011 |
| The synthesis of a benzamidine‐containing NR2B‐selective NMDA receptor ligand labelled with tritium or fluorine‐18 TG Hamill, JA McCauley, HD Burns Journal of Labelled Compounds and Radiopharmaceuticals: The Official Journal …, 2005 | 33 | 2005 |
